Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Xeris Biopharma Holdings (XERS) Net Margin (2020 - 2025)

Historic Net Margin for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to 0.83%.

  • Xeris Biopharma Holdings' Net Margin rose 298400.0% to 0.83% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.88%, marking a year-over-year increase of 278100.0%. This contributed to the annual value of 27.0% for FY2024, which is 109800.0% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Net Margin stood at 0.83%, which was up 298400.0% from 2.7% recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Net Margin high stood at 0.83% for Q3 2025, and its period low was 308.95% during Q2 2021.
  • In the last 5 years, Xeris Biopharma Holdings' Net Margin had a median value of 46.71% in 2024 and averaged 87.65%.
  • Its Net Margin has fluctuated over the past 5 years, first plummeted by -650200bps in 2021, then skyrocketed by 2054800bps in 2022.
  • Over the past 5 years, Xeris Biopharma Holdings' Net Margin (Quarter) stood at 237.02% in 2021, then skyrocketed by 84bps to 39.01% in 2022, then rose by 23bps to 30.16% in 2023, then surged by 72bps to 8.51% in 2024, then surged by 110bps to 0.83% in 2025.
  • Its Net Margin was 0.83% in Q3 2025, compared to 2.7% in Q2 2025 and 15.34% in Q1 2025.